Alfa Cytology offers specialized radiolabeling and antibody-radionuclide conjugate development to advance radiopharmaceutical and nuclear medicine research.

Seventy-five percent of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) who were treated with the antibody ...

ADCs combine antibodies with drug payloads for targeted therapy, but complex manufacturing requires monitoring CQAs across multiple entities.

An effective, affordable, multivalent meningococcal conjugate vaccine is needed to prevent epidemic meningitis in the African meningitis belt. Data on the safety and immunogenicity of NmCV-5, a ...

Preclinical results indicate new approach could be a way to deliver treatment directly to tumors at higher doses, while reducing side effects in healthy tissue.